...Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix N.V....

...MM. AstraZeneca plc has AZD5991, an MCL1 inhibitor, in Phase I testing for hematologic malignancies. Complix N.V....

...Inc. has AMG 176, a MCL1 inhibitor, in Phase I testing for multiple myeloma (MM). Complix N.V....

...AMG 176, an MCL1 inhibitor, in Phase I testing to treat relapsed or refractory MM. Complix N.V....

...FOG Pharmaceuticals Inc. and Aileron Therapeutics Inc. are developing stapled α-helical peptides for cancer and Complix N.V....
...peptide inhibitors, antibodies, or vaccines. Companies and Institutions Mentioned Aileron Therapeutics Inc. (NASDAQ:ALRN), Cambridge, Mass. Complix N.V....

...a MCL1 inhibitor, in Phase I testing to treat relapsed or refractory multiple myeloma (MM). Complix N.V....

...Co. Inc. became the first pharma to disclose a play in the field, partnering with Complix N.V....
...class. I think biologicals for intracellular targets will be one of those new fields,” said Complix...
...transport (A) , or to directly transport the cargo across the cell membrane (B) . Complix N.V....

...AMG 176 , a MCL1 inhibitor, in Phase I testing to treat multiple myeloma (MM). Complix N.V....

...partnered with Merck to discover and develop cancer treatments using Complix’s Cell-Penetrating Alphabodies (CPABs) technology. Complix...
...will have an option to receive exclusive, worldwide rights to compounds generated under the deal. Complix...
...declined to provide further details or financial terms. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Complix N.V....

...Inc. (NYSE:MRK) to develop Cell-Penetrating Alphabodies (CPABs) against up to two undisclosed intracellular cancer targets. Complix...
...payment and milestones, plus tiered royalties. Merck declined to discuss details of the deal, and Complix...
...to an inquiry. CPABs are small proteins capable of binding to intracellular targets. According to Complix...